What FLT3 inhibitor holds the greatest promise?

Publication date: Available online 20 September 2018Source: Best Practice &Research Clinical HaematologyAuthor(s): Richard M. StoneAbstractDetermining which FLT3 inhibitor holds the greatest promise is a difficult task, as the drugs vary according to potency, specificity, protein-binding, drug interactions, and side effect profile. The best choice depends on when in the course of the disease the inhibitor will be used. Moreover, as the results of ongoing trials become available, newer agents could supplant former ‘best’ drugs. This paper reviews FLT3 inhibitors in combination with chemotherapy early in the disease in FLT3 mutant patients, as single agents or in combination in advanced disease, or in the post-transplant setting to provide separate answers to the main question.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research

Related Links:

ConclusionsAbdominal wall defects from resection of cancerous masses of the abdominal wall can be closed with a contralateral rectus abdominis muscle transplant in the absence of mesh.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
In conclusion, 3.1-PP4 is a highly promising lead towards development of a topical treatment for severely infected skin injuries.
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Source: Annals of Hematology - Category: Hematology Source Type: research
In conclusion, our data show how oncogenic and tumor-suppressive drivers of cellular senescence act to regulate surveillance processes that can be circumvented to enable SnCs to elude immune recognition but can be reversed by cell surface-targeted interventions to purge the SnCs that persist in vitro and in patients. Since eliminating SnCs can prevent tumor progression, delay the onset of degenerative diseases, and restore fitness; since NKG2D-Ls are not widely expressed in healthy human tissues and NKG2D-L shedding is an evasion mechanism also employed by tumor cells; and since increasing numbers of B cells express NKG2D ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In addition to the mysteries and autobiographies that some of you may be packing for a late summer vacation or long weekend, consider including the current issue of N2. Each article has a plot that will leave you on edge, and here, I will introduce some of them. It is well known that the presentation of MS is diverse, with some patients presenting early with very mild disease and others presenting late with extensive damage from silent disease. Until now, the best biomarker of disease activity and treatment effects has been the MRI. However, MRI has several limitations, including availability, cost, interscan variability, ...
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Editor ' s Corner Source Type: research
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem cells after exposure to radiation. If the results can be replicated in humans, the compound could help people recover quicker from chemotherapy, radiation and bone marrow transplants.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem cells after exposure to radiation. If the results can be replicated in humans, the compound could help people recover quicker from chemotherapy, radiation and bone marrow transplants.The study, published in Nature Communications,also sheds light on the basic biology behind blood stem cell regeneration and the role of a specific molecular process that is blocked by the new drug. Blood stem cells reside in the bone marrow and produce all of the body ’s blood and immune cells.“We’re very excite...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
High-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) is the standard of care for relapsed or primary refractory (rel/ref) chemorefractory diffuse large B-cell lymphoma. Only 50% of patients are cured with this approach. We investigated safety and efficacy of CD19-specific chimeric antigen receptor (CAR) T cells administered following HDT-ASCT. Eligibility for this study includes poor-risk rel/ref aggressive B-cell non-Hodgkin lymphoma chemosensitive to salvage therapy with: (1) positron emission tomography–positive disease or (2) bone marrow involvement. Patients underwe...
Source: Blood - Category: Hematology Authors: Tags: Immunobiology and Immunotherapy, Transplantation, Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
Squamous cell carcinoma, characterized by large keratinizing and atypical polygonal cells in the respiratory bronchial epithelium [1], affects 30% of patients with lung cancer [2]. Historically, patients with squamous NSCLC were treated with first-line platinum-based chemotherapy [3]. Unlike non-squamous NSCLC, there have been no validated, targetable oncogenic drivers to date. The development and recent approval of targeted immunotherapies, either alone or in combination with platinum-doublet chemotherapy based on improved overall survival, offer a new treatment approach for patients with advanced squamous NSCLC.[4,5] How...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
THE QUESTIONWhat is better, myeloablative chemotherapy-based conditioning or total body irradiation (TBI)-based conditioning for younger (
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Chemotherapy | Hematology | Transplants